Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 23:34 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease
NCT02080364 · vTv Therapeutics · PHASE3 · terminated · last registry update 2021-05-07 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Not due to safety but due to a lack of efficacy at the 5 mg azeliragon dose.” | – | Registry record, vTv Therapeutics |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against AGER within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-01-21Results posted on the registry: vTv Therapeutics, Azeliragon + Placebo (NCT03980730)
- 2022-01-21Also stopped (terminated): vTv Therapeutics, Azeliragon + Placebo (NCT03980730)
- 2021-06-01Results posted on the registry: vTv Therapeutics, Azeliragon 5mg (NCT02916056)
- 2021-06-01Also stopped (terminated): vTv Therapeutics, Azeliragon 5mg (NCT02916056)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision